Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • NEWS AND VIEWS

Jekyll and Hyde flip of the script when bacteria invert gene sequences

If a cell can diversify its own genome, this can be advantageous in the face of changing environmental conditions. Bacteria have been found that can alter encoded proteins by using the trick of sequence inversion inside genes.
By
  1. Chia-Chi Chang

    1. Chia-Chi Chang is in the Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.

  2. Robert R. Jenq

    1. Robert R. Jenq is in the Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California 91010, USA.

Random mutation is a powerful approach used by many organisms, including bacteria, to generate genomic changes that can lead to improved success (fitness) when encountering altered conditions in their environment. However, drawbacks to relying on random mutation include the relatively slow rate of genetic change in rare organisms, as well as a lack of genetic specificity. An alternative strategy of rapidly producing changes at specific genomic sites is called phase variation and this can give rise to variation in the characteristics of cells (phenotypic heterogeneity). DNA-sequence inversion is one form of phase variation, in which DNA-binding proteins and enzymes called recombinases can reversibly flip the orientation of a region of the genome, called an inverton, that is flanked by protein-binding sites1.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 634, 42-43 (2024)

doi: https://doi.org/10.1038/d41586-024-02807-6

References

  1. Jiang, X. et al. Science 363, 181–187 (2019).

    Article  PubMed  Google Scholar 

  2. Chanin, R. B. et al. Nature 634, 234–242 (2024).

    Article  Google Scholar 

  3. Musumeci, O. et al. Am. J. Hum. Genet. 66, 1900–1904 (2000).

    Article  PubMed  Google Scholar 

  4. Zieg, J., Silverman, M., Hilmen, M. & Simon, M. Science 196, 170–172 (1977).

    Article  PubMed  Google Scholar 

  5. D’Souza, G. et al. Evolution 68, 2559–2570 (2014).

    Article  PubMed  Google Scholar 

Download references

Competing Interests

R.R.J. is an adviser for Seres Therapeutics, MaaT Pharma, Prolacta Bioscience and Postbiotics Plus, and has patents licensed to Seres Therapeutics.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links